Salmeterol (xinafoate)

Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].

Product Specifications

CAS Number

[94749-08-3]

Product Name Alternative

GR 33343X xinafoate

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Salmeterol-xinafoate.html

Purity

99.92

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(C1=CC=C2C=CC=CC2=C1O)O.OC3=C(CO)C=C(C(CNCCCCCCOCCCCC4=CC=CC=C4)O)C=C3

Molecular Formula

C36H45NO7

Molecular Weight

603.75

Precautions

H302, H315, H319

References & Citations

[1]Panayiotis A Procopiou, et al. The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group. Bioorg Med Chem. 2011 Oct 15;19 (20) :6026-32.|[2]Malcolm Johnson. Effects of beta2-agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol. 2002 Dec;110 (6 Suppl) :S282-90.|[3]Zhiyuan Wang, et al. Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease. Exp Ther Med. 2018 Feb;15 (2) :1538-1545.